S100钙结合蛋白A9(S100A9)等多因子检测试剂盒(流式荧光发光法)

Multiplex Assay Kit for S100 Calcium Binding Protein A9 (S100A9) ,etc. by FLIA (Flow Luminescence Immunoassay)

MRP14; MIF; 60B8AG; CFAG; NIF; CAGB; CGLB; L1AG; P14; Calgranulin B; Migration inhibitory factor-related protein 14; Calprotectin L1H subunit; Leukocyte L1 complex heavy chain

(注:单次混测多因子不超过8个指标 )

  • S100钙结合蛋白A9(S100A9)等多因子检测试剂盒(流式荧光发光法)产品包装(模拟)
  • S100钙结合蛋白A9(S100A9)等多因子检测试剂盒(流式荧光发光法)产品包装(模拟)
  • Certificate通过ISO 9001、ISO 13485质量体系认证

特异性

本试剂盒用于检测S100钙结合蛋白A9(S100A9)等多因子检测试剂盒(流式荧光发光法),经检测与其它相似物质无明显交叉反应。
由于受到技术及样本来源的限制,不可能完成对所有相关或相似物质交叉反应检测,因此本试剂盒有可能与未经检测的其它物质有交叉反应。

回收率

分别于定值血清及血浆样本中加入一定量的S100钙结合蛋白A9(S100A9)等多因子检测试剂盒(流式荧光发光法)(加标样品),重复测定并计算其均值,回收率为测定值与理论值的比率。

样本回收率范围(%)平均回收率(%)
serum(n=5)80-9080
EDTA plasma(n=5)82-9186
heparin plasma(n=5)79-9083
sodium citrate plasma(n=5)93-105101

精密度

精密度用样品测定值的变异系数CV表示。CV(%) = SD/mean×100
批内差:取同批次试剂盒对低、中、高值定值样本进行定量检测,每份样本连续测定20 次,分别计算不同浓度样本的平均值及SD值。
批间差:选取3个不同批次的试剂盒分别对低、中、高值定值样本进行定量测定,每个样本使用同一试剂盒重复测定8次,分别计算不同浓度样本的平均值及SD值。
批内差: CV<10%
批间差: CV<12%

线性

在定值血清及血浆样本内加入适量的S100钙结合蛋白A9(S100A9)等多因子检测试剂盒(流式荧光发光法),并倍比稀释成1:2,1:4,1:8,1:16的待测样本,线性范围即为稀释后样本中S100钙结合蛋白A9(S100A9)等多因子检测试剂盒(流式荧光发光法)含量的测定值与理论值的比率。

样本1:21:41:81:16
serum(n=5)84-103%86-94%78-105%86-97%
EDTA plasma(n=5)87-94%90-104%92-101%79-90%
heparin plasma(n=5)80-101%78-90%80-103%87-98%
sodium citrate plasma(n=5)78-102%84-93%97-104%79-91%

稳定性

经测定,试剂盒在有效期内按推荐温度保存,其活性降低率小于5%。
为减小外部因素对试剂盒破坏前后检测值的影响,实验室的环境条件需尽量保持一致,尤其是实验室内温度、湿度及温育条件。其次由同一实验员来进行操作可减少人为误差。

实验流程

1. 实验前标准品、试剂及样本准备;
2. 加样(标准品、样本、磁珠)标准品或样本100μL及磁珠10μL,
    37°C酶标板振荡器孵育90分钟;
3. 磁吸甩干,加检测溶液A100μL,37°C酶标板振荡器孵育60分钟;
4. 磁吸洗板3次;
5. 加检测溶液B100μL,37°C振动孵育30分钟;
6. 磁吸洗板3次;
7. 加鞘液100μL,旋涡震荡2分钟后读数。

实验原理

将S100钙结合蛋白A9(S100A9)等多因子检测试剂盒(流式荧光发光法)抗体包被于磁珠,制成固相载体,向微孔中分别加入标准品或标本以及磁珠,其中的S100钙结合蛋白A9(S100A9)等多因子检测试剂盒(流式荧光发光法)与连接于固相载体上的抗体结合,然后加入生物素化的S100钙结合蛋白A9(S100A9)等多因子检测试剂盒(流式荧光发光法)抗体,将未结合的生物素化抗体洗净后,加入PE标记的亲和素,再次彻底洗涤后即可上机读数。MFI值和样品中的S100钙结合蛋白A9(S100A9)等多因子检测试剂盒(流式荧光发光法)呈正相关。

赠品

相关产品

编号适用物种:Mus musculus (Mouse,小鼠)应用(仅供研究使用,不用于临床诊断!)
RPB793Mu02S100钙结合蛋白A9(S100A9)重组蛋白Positive Control; Immunogen; SDS-PAGE; WB.
APB793Mu01S100钙结合蛋白A9(S100A9)活性蛋白Cell culture; Activity Assays.
RPB793Mu01S100钙结合蛋白A9(S100A9)重组蛋白Positive Control; Immunogen; SDS-PAGE; WB.
PAB793Mu01S100钙结合蛋白A9(S100A9)多克隆抗体WB
PAB793Mu02S100钙结合蛋白A9(S100A9)多克隆抗体WB; IHC; ICC; IP.
LAB793Mu81S100钙结合蛋白A9(S100A9)多克隆抗体(异硫氰酸荧光素标记)WB; IHC; ICC; IF.
LAB793Mu71S100钙结合蛋白A9(S100A9)多克隆抗体(生物素标记)WB; IHC; ICC.
SEB793MuS100钙结合蛋白A9(S100A9)检测试剂盒(酶联免疫吸附试验法)Enzyme-linked immunosorbent assay for Antigen Detection.
LMB793MuS100钙结合蛋白A9(S100A9)等多因子检测试剂盒(流式荧光发光法)FLIA Kit for Antigen Detection.
KSB793Mu01S100钙结合蛋白A9(S100A9)检测试剂盒DIY材料(酶联免疫吸附试验法)自己动手制作ELISA试剂盒的主要材料

参考文献

杂志参考文献
J. Proteome Res.Differential Proteomic Analysis Distinguishes Tissue Repair Biomarker Signatures in Wound Exudates Obtained from Normal Healing and Chronic Wounds[Pubmed: source]
Biochemical and Biophysical Research CommunicationsHigh circulating levels of S100A8/A9 complex (calprotectin) in male Japanese with abdominal adiposity and dysregulated expression of S100A8 and S100A9 in adipose tissues of obese mice[ScienceDirect: S0006291X1200352X]
PLoS One. Proteins with Altered Levels in Plasma from Glioblastoma Patients as Revealed by iTRAQ-Based Quantitative Proteomic Analysis[PubMed: 23029420]
MainzIdentifizierung neuer potentieller Biomarker für das Kolonkarzinom sowie dessen Vorstufen[Info:Source]
PLOS ONESusceptibility to COPD: Differential Proteomic Profiling after Acute Smoking[Pubmed:25036363]
the faseb journalSoluble receptor for advanced glycation end products inhibits disease progression in autosomal dominant polycystic kidney disease by down-regulating cell proliferation[PubMed: 25934702]
Sci Rep. S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabine[pmc:PMC4810364]
Journal of Alzheimer's DiseaseProteomics Analysis of Blood Serums from Alzheimer's Disease Patients Using iTRAQ LabelingTechnology.[pubmed:27911324]
International journal of molecular sciences Immune Modulating Topical S100A8/A9 Inhibits Growth of Pseudomonas aeruginosa and Mitigates Biofilm Infection in Chronic Wounds.[pubmed:28672877]
GastroenterologyTu1938-Micronutrients Assessment in Patients with Cirrhosis[10.1016:S0016-5085(18)33544-3]
GastroenterologyTu1942-PI3K/AKT-Mediated Upregulation of C7 Inhibits Colorectal Cancer Proliferation and Metastasis[10.1016:S0016-5085(18)33544-5]
Journal of Biological ChemistrySignaling between pancreatic β-cells and macrophages via S100 calcium-binding protein A8 exacerbates β-cell apoptosis and islet inflammation[Pubmed:29496993]
Cancer Management and ResearchThe role of calgranulin B gene on the biological behavior of squamous cervical cancer in vitro and in vivo[Pubmed:29497331]
European review for medical and pharmacological sciencesS100A8/A9 promotes MMP-9 expression in the fibroblasts from cardiac rupture after myocardial infarction by inducing macrophages secreting TNFα.[Pubmed:29949169]
Estudio de células inmunosupresoras y biomarcadores circulantes en carcinoma renal[]
LungMass Spectrometry Analysis of the Exhaled Breath Condensate and Proposal of Dermcidin and S100A9 as Possible Markers for Lung Cancer Prognosis[Pubmed: 31115649]
中国医药导报降钙素原, 超敏C 反应蛋白, 红细胞沉降率及S100A9 对肺结核合并肺部细菌感染的影响[]
scandinavian journal of clinical & laboratory investigationSerum S100A6, S100A8, S100A9 and S100A11 proteins in colorectal neoplasia: results of a single centre prospective study[Pubmed: 31856598]
PLoS OneAdverse reproductive effects of S100A9 on bovine sperm and early embryonic development in vitro[Pubmed: 31945120]
Sci RepOverexpression of S100A9 in tumor stroma contribute to immune evasion of NK/T cell lymphoma and predict poor response rate[34045609]
university of copenhagenAdjunctive S100A8/A9 Immunomodulation Hinders Cipro fl oxacin Resistance in[]